TY - JOUR T1 - Quality of life after transcatheter or surgical aortic valve replacement using the Toronto Aortic Stenosis Quality of Life Questionnaire JF - Open Heart JO - Open Heart DO - 10.1136/openhrt-2021-001821 VL - 8 IS - 2 SP - e001821 AU - Simon Kennon AU - Rima Styra AU - Nikolaos Bonaros AU - Lukas Stastny AU - Mauro Romano AU - Thierry Lefèvre AU - Carlo Di Mario AU - Pierluigi Stefàno AU - Flavio Luciano Ribichini AU - Dominique Himbert AU - Marina Urena-Alcazar AU - Jorge Salgado-Fernandez AU - Jose Joaquin Cuenca Castillo AU - Bruno Garcia AU - Cornelia Deutsch AU - Lenka Sykorova AU - Jana Kurucova AU - Martin Thoenes AU - Claudia Lüske AU - Peter Bramlage AU - Derk Frank Y1 - 2021/11/01 UR - http://openheart.bmj.com/content/8/2/e001821.abstract N2 - Background The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) is a validated instrument for assessing quality of life (QoL) in patients with severe aortic stenosis (AS). In this study, we evaluated health status outcomes, based on the TASQ, in patients with severe AS undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).Methods The TASQ registry was a prospective observational registry. Patients with severe AS from nine centres in Europe and one in Canada underwent either SAVR or transfemoral TAVR. Patients completed the TASQ, Kansas City Cardiomyopathy Questionnaire and Short Form-12 V.2 prior to the intervention, predischarge, and at 30-day and 3-month follow-ups. Primary end point was the TASQ score.Results In both the TAVR (n=137) and SAVR (n=137) cohorts, significant increases were observed in all three scores. The overall TASQ score improved as did all but one of the individual domains at 3 months after the intervention (p<0.001). TASQ health expectations were the only domain which worsened (p<0.001). Across TASQ subscores, significant changes were evident from the time of discharge in the TAVR and 30-day follow-up in the SAVR cohort. In a categorical analysis of the TASQ, 39.7% of the TAVR group and 35.0% of the SAVR group had a substantially improved health status at 3 months compared with baseline.Conclusions The TASQ captured changes in QoL among patients with severe AS who were treated with TAVR or SAVR. QoL improved substantially after either intervention, as indicated by changes in the TASQ overall score at 3 months.Trial registration number NCT03186339.Data are available upon reasonable request. ER -